Legal Issues Arising From the Use of Artificial Intelligence in Drug Development

Artificial intelligence (AI) is reshaping drug discovery and development, enabling companies to accelerate research, optimize clinical strategies, and enhance manufacturing and operational efficiency. As adoption expands, so do the regulatory, intellectual property, data protection, and contractual complexities that can affect approvals, transactions, and long-term value. In this article, published by Drug Discovery World, Sidley partners Adriana Tibbitts, Alison Lehner, Frank Rahmani, and Jason Kropp examine the evolving legal landscape surrounding AI in drug development and outline practical steps organizations can take to mitigate risk while capturing its benefits. Read the full article to gain deeper insight into these timely considerations.